Athena puts profit on the horizon

Changes Athena Neurosciences Inc. made in its product portfolio last week should increase near-term revenues, save money and bring profitability by 1995, according to analysts.

The return to A.H. Robins of world rights to dezinamide (AN051), an anticonvulsant to treat epilepsy, will save ATHN $16 million to $20 million in development costs, according to CFO Matthew Megaro. ATHN had already invested $6 million in its development...